CD30 CAR T-cells Post AutoHSCT for Poor-risk Hodgkin Lymphoma
This study is for young people aged 6 to 29 with classical Hodgkin Lymphoma (a type of cancer that starts in white blood cells called lymphocytes) that is considered "poor-risk." This means the cancer has come back or didn't respond well to previous treatments. You would first receive strong chemotherapy (myeloablative chemotherapy, MAC) followed by an autologous stem cell transplant (AutoHSCT), which uses your own healthy stem cells. Then, 21-42 days later, you would receive an infusion of CD30 CAR T-cells. These are your own immune cells that have been specially trained to find and fight your cancer. The study aims to see how safe this treatment is and if the CAR T-cells can be successfully made for patients. The study plans to enroll 21 participants, but its current status is unclear.
- Study design
- This is an interventional study, meaning participants receive a specific treatment. It plans to enroll 21 participants.
- What's involved
- You would undergo screening, have blood collected for CAR T-cell manufacturing, and have your stem cells collected. You would then receive chemotherapy, an autologous stem cell transplant, and finally the CD30 CAR T-cell infusion.
- Compensation
- Not stated in the trial record.
- Follow-up
- The study will track your safety for 2 years after receiving the CAR T-cells.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
CD30 CAR T-cells Post AutoHSCT for Poor-risk Hodgkin Lymphoma
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Mitchell S Cairo, MD · PRINCIPAL_INVESTIGATOR · New York Medical College
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
What this trial measures
- Safety of administering CAR T-cells2 years
To evaluate the incidence of adverse events related to autologous CD30+ CAR T-cell infusions including not limited to infusions related reactions (IRR) (CTCAE 5.0), cytokine release syndrome (CRS) (ASCTC), and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) (ASCTC) and all general grade 3-5 toxicities (CTCAE 5.0) in children, adolescent, and young adult patients with poor-risk CD30+ cHL following MAC AutoHSCT.
- Feasibility of Central Manufacturing of CAR T-cells1 year
To evaluate the feasibility of local site PBMC collection and central GMP CD30 CAR T cell manufacturing with a 75% success rate in children, adolescent, and young adult patients with poor-risk CD30+ cHL following MAC AutoHSCT.